Type 2 Diabetes Treatment | Treatment Advances In Type 2 Diabetes | Healthgrades.com
Diabetes is one of the most common chronic diseases in the United States. With type 2 diabetes being the most common form of the disease, its a priority to make progress in its treatment. And researchers have done just that. This is good news if youor a loved onehave type 2 diabetes. Here are some exciting advances in the treatment of type 2 diabetes. Type 1 diabetes usually comes to mind with insulin. But most people with type 2 diabetes will eventually need to use it. People with type 2 diabetes account for most insulin use due to their sheer numbers. Approximately 30% of type 2 diabetes patients use insulin. So making advances in insulin treatment benefits many people with type 2 diabetes. After you receive a diagnosis of type 2 diabetes, your doctor will work with you to determine the best method of treatment, be it medication or insulin injections. But, as Dr. Anthony Cardillo explains, the most effective treatment for type 2 diabetes? Proper diet and exercise. Medical Reviewer: William C. Lloyd III, MD, FACS Last Review Date: Aug 13, 2015 2018Healthgrades Operating Company, Inc. All rights reserved. May not be reproducedor reprinted without permission from Healthgrades Operating Company, Inc. Useof this information is governed by the Healthgrades User Agreement. If fact, people who are newly diagnosed with type 2 diabetes and whose pancreas can still make insulin, can actually reverse their diabetes by immediately starting short-term insulin and a strict diet and exercise program. In the last 10 years, new types of insulin have come to market. Most are variations of the usual rapid-, short- or long-acting injectable insulin. One very recent newcomer is a totally different form of insulinAfrezza inhaled human insulin. You take this type of insulin by breathing it Continue reading >>
9 Diabetes Breakthroughs You Need To Know About
Diabetes is not just one condition - but whether your body is struggling with blood sugar levels due to type 1, or type 2, or even only during pregnancy, it's a serious condition that requires daily care and still doesn't have a cure. But scientists have been working hard to find cures, new treatments, and better management techniques for the millions of people worldwide dealing with diabetes. Here are some of the latest developments you need to know about. 1. Brand new beta cells. Type 1 diabetes develops when a person's immune system wipes out insulin-producing beta cells in the pancreas. But it turns out that another type of immature beta cell has been hiding in our pancreases all along, and scientists think it might be possible to use these 'virgin beta cells' to restore the functionality of the pancreas. 2. A preventative vaccine. Finnish researchers are about to embark on the first-ever clinical trial for a type 1 diabetes prevention vaccine. While it's not a cure for those who already have the condition, a successful vaccine could potentially prevent thousands of cases each year, as the vaccine targets a virus linked with the development of an autoimmune reaction in the pancreas. 3. A unique transplant. One woman with severe type 1 diabetes has spent a year without insulin injections thanks to an experimental transplant. Doctors implanted insulin-producing cells into a fatty membrane in the stomach cavity, and the success of the operation is paving the way towards more people receiving artificial pancreases. 4. New pancreas tissue. Earlier this year scientists announced that they reversed type 1 diabetes in mice by giving them a transplant of pancreatic tissue. The tissue was grown using stem cells from non-diabetic mice, and the success of this method suggests i Continue reading >>
Recent Advances In Type 1 Diabetes
Mervyn Kyi, John M Wentworth, Alison J Nankervis, Spiros Fourlanos and Peter G Colman Med J Aust 2015; 203 (7): 290-293. || doi: 10.5694/mja14.01691 Type 1 diabetes (T1D) is caused by an autoimmune attack on pancreatic beta cells that leads to insulin deficiency. The incidence of T1D in Australia has doubled over the past 20 years. T1D treatment focuses on physiological insulin replacement, aiming for near-normal blood glucose levels. Hypoglycaemia is a significant cause of morbidity and mortality in T1D. Optimal T1D management is complex, and is enhanced by empowering individuals in all aspects of managing diabetes. New technologies, including insulin pumps, continuous glucose monitors and sensor-augmented pumps, can assist people achieve better glycaemic control and reduce the risk of severe hypoglycaemia. Women with T1D can achieve significantly better outcomes during pregnancy and for their infants by planning for their pregnancy and by intensive glycaemic control. Several trials are underway that seek to identify the determinants of autoimmunity and to develop therapies that prevent T1D in at-risk individuals. Pancreatic and islet cell transplants are proven therapies, but are only offered to individuals with diabetes and renal failure (pancreas) or severe hypoglycaemia unawareness (islet cell transplants). Although T1D is still associated with considerable premature mortality, recent findings show that a significant improvement in life expectancy has occurred. Type 1 diabetes (T1D) affects around 120 000 Australians, half of whom are diagnosed in adulthood. 1 It is caused by the immune-mediated destruction of pancreatic beta cells, leading to insulin deficiency, hyperglycaemia and the risk of ketoacidosis. Antibodies directed against the beta-cell antigens insuli Continue reading >>
Diabetes Research: Advancing Toward A Cure
George L. King, M.D. Research Director and Head of the Section on Vascular Cell Biology, Joslin Diabetes Center; Professor of Medicine, Harvard Medical School This is an incredibly exciting time in diabetes research. In the past, we only have had one promising approach to finding a cure for patients with type 1 diabetes. Now we have several possibilities related to a cure, and even prevention, both for type 1 and type 2 diabetes. Previously, research toward a cure was focused on transplantation of the cells in the pancreas that produce insulin, the islet cells or parts of the pancreas. In type 1 diabetes, the body’s immune system turns on itself and destroys these islet cells. As a result, the body can’t produce the insulin required to escort glucose from the food we eat to where it is needed—into the cells of the body’s muscles and other organs. We are now focusing on ways to understand this immune attack to find safe ways to block it. There are several ongoing studies using our knowledge of immunology to try to intervene and prevent type 1 diabetes. Another important effort is directed to regenerating islet cells—to produce insulin again—either through the use of stem cells, embryonic or adult, or other ways of engineering these cells. We are now hopeful that a large number of people with type 1 diabetes still have surviving islet cells left to regrow. This optimism has been raised by the findings that many type 1 diabetes patients may still have residual islets that have retained some function to make insulin. A recent Joslin study of people who have lived more than 50 years with type 1 diabetes indicated that even some of these patients can still make insulin. Much attention is also aimed at the causes of type 2 diabetes. The main theory involves inflamm Continue reading >>
7 Innovations That Are Changing The Way We Manage Diabetes, A Disease That Affects 371 Million People Worldwide
It's been almost a century since researchers discovered a way to treat diabetes. Since then, there have been a number of medical and technological advances that aim to make the lives of people living with diabetes — both type 1 and type 2 — more manageable. Around the globe, the group of conditions affects 371 million people worldwide, a number that's expected to increase to 552 million by 2030. From monitoring blood sugar levels — a taxing experience that people with diabetes must grow used to doing every day — to ways that make insulin easier to deliver, here are some of the innovations that are changing the way we manage diabetes. Medtronic created the world's first 'artificial pancreas.' In September, the FDA approved a device that's often referred to as an "artificial pancreas" for use in people with type 1 diabetes over age 14. The device, made by Medtronic, is called the MiniMed 670G, and it works by automatically monitoring a person's blood sugar levels and administering insulin as needed — no constant checking and injecting required. That way, it can act like a pancreas, the organ in our bodies that in healthy people is able to moderate our blood sugar levels by pumping out insulin that can process the sugars found in food. Livongo is making a glucose monitor that can get software updates just like your phone. "No one cares about the technology," Glen Tullman, the CEO of California-based startup Livongo and whose son has Type 1 diabetes, told Business Insider. "They simply want to live their life." On Wednesday, the company added the capability for the monitor to receive software updates, eliminating the need for people to constantly upgrade to new glucose meters when the technology advances. Livongo also offers the testing strips the machine uses for Continue reading >>
Recent Advances In The Pathogenesis, Prevention And Management Of Type 2 Diabetes And Its Complications
DOI: 10.5772/1541 Edited Volume Type 2 diabetes "mellitus" affects nearly 120 million persons worldwide- and according to the World Health Organization this number is expected to double by the year 2030. Owing to a rapidly increasing disease prevalence, the medical, social and economic burdens associated with the microvascular and macrovascular complications of type 2 diabetes are likely to increase dramatically in the coming decades. In this volume, leading contributors to the field review the pathogenesis, treatment and management of type 2 diabetes and its complications. They provide invaluable insight and share their discoveries about potentially important new techniques for the diagnosis, treatment and prevention of diabetic complications. Continue reading >>
Advances In Medical Technology
Improving Diabetes Care Treatment of diabetes, like most areas of medicine, has changed considerably over the years as a result of technological advances. From the discovery, purification, and mass production of insulin to the development of less painful ways to deliver it, the lives of people with diabetes have been improved — and sometimes greatly extended — by both diabetes-focused research and broader improvements in medical care. Although it can be difficult to predict the impact of an emerging technology, there are several exciting developments on the horizon that may soon significantly change how people with diabetes receive medical care or manage the condition on their own. At least one relatively new innovation, the continuous glucose monitor, is already changing the daily routine for some. This article examines several innovations that are likely to change — or are already changing — the way medical care is delivered and the way medical information is communicated. Not all assessments of medical technology are completely upbeat, however. Especially when it comes to electronic health records, many experts are either frustrated at the pace of progress or skeptical of how the technology will be used. Electronic health records Dr. Richard Hellman, who is past-president of the American Association of Clinical Endocrinologists and has an endocrinology practice in North Kansas City, Missouri, laments that although someone can get money from an ATM or use a credit card anywhere in the world, medical information often cannot be easily accessed when it is needed. “The tragedy is that information doesn’t move around to the benefit of the patient,” he says. “There is much too much information that can’t be transmitted.” The problem is not a technologic Continue reading >>
People With Diabetes Losing Disability Tax Credit Because Of 'advances In Technology': Minister
People with diabetes losing disability tax credit because of 'advances in technology': minister Published Monday, October 23, 2017 10:00PM EDT According to a letter obtained by CTV News, advances in technology is the reason that most adults with diabetes now dont qualify for a disability credit that can reduce their tax bills by as much as $1,500 a year. In the July 31, 2017 letter, Revenue Minister Diane Lebouthillier explained that in order to receive a disability tax credit under the Income Tax Act, one must require life-sustaining therapy (LST) at least three times each week for a total period averaging at least 14 hours a week to sustain a vital function. In the case of portable devices like insulin pumps, the time that the device takes to deliver the therapy does not count toward the 14-hour requirement, Lebouthillier added in the letter. Activities like following a dietary restriction, exercising, traveling to receive therapy, going to medical appointments, shopping for medication, or recuperating after therapy do not count towards the 14-hour requirement. A leading reason for people with diabetes losing their special tax status, the letter suggested, are modern, portable insulin pumps. In general, and with consideration given to recent advances in technology, adults who independently manage their insulin therapy on a regular basis are unlikely to meet the 14-hours-per-week requirement, Lebouthillier wrote. According to Diabetes Canada , as many as 150,000 Canadians now stand to lose their disability tax credit under the Liberal governments current interpretation of the Income Tax Act, which seems to have been adopted early this year. Diabetes sufferers have been eligible for the disability tax credit for over a decade, but now this government is stripping it aw Continue reading >>
Recent Advances In Biomaterials For The Treatment Of Diabetic Foot Ulcers
Recent advances in biomaterials for the treatment of diabetic foot ulcers b Department of Biomedical Engineering, Carnegie Mellon University, 5000 Forbes Ave, Pittsburgh, USA Diabetes mellitus is one of the most challenging epidemics facing the world today, with over 300 million patients affected worldwide. A significant complication associated with diabetes is hyperglycemia, which impairs wound healing. The rise in the diabetic patient population in recent years has precipitated an increase in the incidence and prevalence of chronic diabetic wounds, most commonly the diabetic foot ulcer. Although foot ulcers are difficult to treat due to their complicated pathology, outcomes have improved with the development of increasingly sophisticated biomaterials that accelerate healing. In this review, we describe recently developed biomaterials that elicit healing through cellmaterial interactions and/or the sustained delivery of drugs. These tunable therapeutic systems increase angiogenesis, collagen deposition, cell proliferation, and growth factors concentrations, while decreasing inflammation and enzymatic degradation of the extracellular matrix. As the field of biomaterials for wound healing continues to mature, we expect to witness a broader range of clinical options that will speed healing times and improve patient quality of life. This article is part of the themed collection: Emerging Investigators 2017 The article was received on 28 Mar 2017, accepted on 14 Aug 2017and first published on 15 Aug 2017 Recent advances in biomaterials for the treatment of diabetic foot ulcers L. N. Kasiewicz and K. A. Whitehead, Biomater. Sci., 2017,5, 1962 If you are not the author of this article and you wish to reproduce material from it in a third party non-RSC publication you must fo Continue reading >>
Current Advances In The Biochemical And Physiological Aspects Of The Treatment Of Type 2 Diabetes Mellitus With Thiazolidinediones
Current Advances in the Biochemical and Physiological Aspects of the Treatment of Type 2 Diabetes Mellitus with Thiazolidinediones D. Alemn-Gonzlez-Duhart ,1 F. Tamay-Cach ,2 S. lvarez-Almazn ,1and J. E. Mendieta-Wejebe 1 1Laboratorio de Biofsica y Biocatlisis, Seccin de Estudios de Posgrado e Investigacin, Escuela Superior de Medicina, Instituto Politcnico Nacional, Plan de San Luis y Salvador Daz Mirn, Casco de Santo Toms, 11340 Ciudad de Mxico, DF, Mexico 2Laboratorio de Investigacin en Bioqumica, Departamento de Formacin Bsica Disciplinaria y Seccin de Estudios de Posgrado e Investigacin, Escuela Superior de Medicina, Instituto Politcnico Nacional, Plan de San Luis y Salvador Daz Mirn, Casco de Santo Toms, 11340 Ciudad de Mxico, DF, Mexico Received 18 March 2016; Accepted 24 April 2016 Copyright 2016 D. Alemn-Gonzlez-Duhart et al. This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The present review summarizes the current advances in the biochemical and physiological aspects in the treatment of type 2 diabetes mellitus (DM2) with thiazolidinediones (TZDs). DM2 is a metabolic disorder characterized by hyperglycemia, triggering the abnormal activation of physiological pathways such as glucose autooxidation, polyols pathway, formation of advance glycation end (AGE) products, and glycolysis, leading to the overproduction of reactive oxygen species (ROS) and proinflammatory cytokines, which are responsible for the micro- and macrovascular complications of the disease. The treatment of DM2 has been directed toward the reduction of hyperglycemia using different drugs such as insulin sensitizers, as the case of Continue reading >>
Important Advances In Type 1 Diabetes Research
Home / Conditions / Type 1 Diabetes / Important Advances in Type 1 Diabetes Research Important Advances in Type 1 Diabetes Research JDRF-funded studies on development of artificial pancreas, encapsulated islet cell therapies, and kidney preservation presented at 2015 ADA Scientific Sessions. Researchers at the University of Virginia are working to make the idea of an artificial pancreas a reality for anyone who needs it. Dr. Boris Kovatchev and his research team have developed a Diabetes Assistant Artificial Pancreas (DiAs AP) algorithm that can be used continuously in individuals with type 1 diabetes to help monitor their blood glucose levels and keep them in range all day and night. The target range is 70 180 mg/dL. According to their findings, the DiAs system is capable of reducing the amount of hypoglycemia experienced by type 1 diabetics, increasing the amount of time in range, and improving overnight control of blood glucose. Due to their promising preliminary results, research can now be expanded to a larger population, which could also include system options for use in children, teens, and pregnant women. Another focus of JDRF research has been the development of a new process that would allow for a significant decrease in the amount of time it takes researchers to create insulin-producing islet cells from human stem cells that would then be used in encapsulated islet cell therapies. Along with that, efforts are being made to pinpoint potential substances that can be used to encapsulate implanted islet cells without causing an immune response. Drs. Timothy Kieffer and Douglas Melton both claim to have developed procedures that shorten new islet cells production time by at least 70%; reducing the time from 20 24 weeks to as little as 6 weeks. The main difference Continue reading >>
Jcm | Free Full-text | Controversies And Advances In Gestational Diabetesan Update In The Era Of Continuous Glucose Monitoring
J. Clin. Med. 2018, 7(2), 11; doi: 10.3390/jcm7020011 Controversies and Advances in Gestational DiabetesAn Update in the Era of Continuous Glucose Monitoring Laboratory of Endocrinology, Federal University of Minas Gerais, Belo Horizonte 30130-100, Brazil Author to whom correspondence should be addressed. Received: 19 November 2017 / Revised: 8 January 2018 / Accepted: 9 January 2018 / Published: 25 January 2018 Diabetes in pregnancy, both preexisting type 1 or type 2 and gestational diabetes, is a highly prevalent condition, which has a great impact on maternal and fetal health, with short and long-term implications. Gestational Diabetes Mellitus (GDM) is a condition triggered by metabolic adaptation, which occurs during the second half of pregnancy. There is still a lot of controversy about GDM, from classification and diagnosis to treatment. Recently, there have been some advances in the field as well as recommendations from international societies, such as how to distinguish previous diabetes, even if first recognized during pregnancy, and newer diagnostic criteria, based on pregnancy outcomes, instead of maternal risk of future diabetes. These new recommendations will lead to a higher prevalence of GDM, and important issues are yet to be resolved, such as the cost-utility of this increase in diagnoses as well as the determinants for poor outcomes. The aim of this review is to discuss the advances in diagnosis and classification of GDM, as well as their implications in the field, the issue of hyperglycemia in early pregnancy and the role of hemoglobin A1c (HbA1c) during pregnancy. We have looked into the determinants of the poor outcomes predicted by the diagnosis by way of oral glucose tolerance tests, highlighting the relevance of continuous glucose monitoring to Continue reading >>
The New Type 2 Diabetes Technologies Pharmacists Need To Know About
The New Type 2 Diabetes Technologies Pharmacists Need to Know About Pharmacists need to stay informed about new technologies in order to help diabetic patients take advantage. New diabetes technology will give patients access to more data about their health status and will add convenience and customization to management strategies. But pharmacists will need to stay informed about these new advances in order to help patients prepare for the changes ahead. "I think that's a big piece of what pharmacists do is educate the patient not only on their disease but on the options that are out there," says Jonathan Marquess, PharmD, CDE, FAPhA, president of the Institute for Wellness and Education, Inc. and owner of 10 independent pharmacies in the Georgia area. Industry experts say that as diabetes technology continues to advance, the tools patients rely on each day to help them manage their diseasewhether they are glucose monitors, insulin pens, or pumpsare also expected to evolve. David T. Ahn, MD, endocrinologist and assistant clinical professor of medicine at UCLA, says that in the future, tools previously used to treat type 1 diabetes will become more accessible for those with the type 2. Related article: Adult Patients Could Be Misdiagnosed with Wrong Form of Diabetes In 2017, Abbott announced the approval of the FreeStyle Libre Flash Glucose Monitoring System. The device is distinctive because it uses a sensor placed on the upper arm. According to Ahn, the Freestyle Libre is a more affordable continuous monitoring system, making it a more appealing treatment option for more patients. "It really hits a convenience and price sweet spot for patients and insurers," he says. For many type 2 diabetes patients, the device may be the first time they are able to trace their blood Continue reading >>
New Advances In Diabetes Care
Titled “The NHS RightCare Pathway Diabetes” NHS England's recent report on diabetes care prioritises seven areas: type 2 diabetes prevention diagnosis structured education care planning foot care inpatient safety a specialist type 1 diabetes service The pathway allows commissioners to compare their existing diabetes service with an optimal diabetes service and provides guidance about optimisation that can be achieved by scaling up local pathways. If you would like to see more detailed information about this blueprint please click here FreeStyle Libre It’s almost certain that one of the early benefits of this new focus is the decision by the NHS to approve FreeStyle Libre on the Drug Tariff which means that, subject to local health economy approval, this innovative technology has been available without cost from November 1st. As it is subject to local decisions, it is not guaranteed to be available to everyone and may therefore only be offered to those with type 1 diabetes who have multiple daily injections of insulin or who self-manage their diabetes using insulin pumps The system is a flash glucose monitoring system which reads glucose levels through a waterproof sensor on the arm rather than via finger pricks. Whilst this does not actually alert users when their glucose levels fall too low it does allow them to review their sugar levels throughout the day and night in a practical form. It was approved for use for those who develop diabetes during pregnancy earlier in the year. The sensor is a few centimetres in diameter and is designed to stay in place – usually on the upper arm - for 14 days. Fibre within the sensor is placed 5mm into the skin (which most people describe as painless) and then, by drawing interstitial fluid from the muscle, measures glucose le Continue reading >>
Advances In Diabetes Care Apple-style
I think we all understand Apple-style at this point. The company drops a product, the buzz explodes, and after the dust cloud settles we often realize that, yes, our lives and the computing landscape around us have indeed been irrevocably changed. But what about Apple and T1D? Let’s start with the deep past. Ten years ago, Amy Tenderich, diabetes advocate and founder of DiabetesMine, wrote an essay called “An Open Letter to Steve Jobs.” IPod sales had recently reached the 100 million mark, and the essay, which went viral, called on Jobs to apply the same technological innovation and brilliance to the design of cutting edge diabetes-care devices. Her thrust: let’s save lives and have convenient access to our music libraries at the same time. Evidence is emerging that Jobs, who died in 2011, listened. Last spring Apple CEO Tim Cook was seen wearing a mysterious Apple Watch tied to a prototype glucose tracker. Rumors about Apple cracking the “holy grail” of diabetes management: a noninvasive CGM system that did not require breaking the skin with a needle sensor or wire began to stir. Around the same time, news reports confirmed that Apple had hired a secret team of scientists and was indeed working on such a project. The here and now This summer Apple announced a fall update to its Health app incorporating the ability to track insulin delivery doses. The update, which is available in the recently released iOS 11 software, includes both basal and bolus insulin delivery tracking. Simply open Health, go to Health Data, click on results, and then insulin to enter data. In the past, Apple Health allowed users to collect diabetes-related information ranging from blood glucose levels, to carb intake, to general activity data. Data was often gathered by secondary healt Continue reading >>
